An initiative by Exscientia and the University of Oxford to accelerate translation of novel biology into drug discovery
Who We Are
Xcellomics is a partnership between Exscientia, the University of Oxford Target Discovery Institute (TDI) and the Global Academic Community. We work together to rapidly translate biological discoveries into drug discovery programs for cancers with unmet clinical need.
Our Mission
Bring together research excellence and industrial expertise to accelerate the translation of functional genomic or compound screening data into first-in-class drug candidates that have the highest chances of addressing unmet clinical need.
Why join Xcellomics?
Academics worldwide are invited to submit proposals for functional genomic CRISPR or high throughput compound screens that address key biological questions to advance therapeutic development for cancers that remain challenging to treat.
Screening at no cost
Selected screens will be developed and run by the University of Oxford TDI at no cost to the academic collaborator.
Milestone payments
Upon successful completion of the screen, academic collaborators may be eligible for a £50,000 milestone payment.
Collaborators will be eligible for an additional £50,000 milestone payment if drug targets identified by the screen are internalized into drug discovery programs by Exscientia.
Retention of data ownership
Academic collaborators will retain co-ownership of all intellectual property and will receive a detailed screening report that includes confirmed hits.
How It Works
We bring together complimentary expertise to expedite efficient drug development.
Crowdsourcing project ideas from innovative academic experts
Cutting edge industry-grade phenotypic and CRISPR screening from the TDI
Leading AI-driven drug discovery and design from Exscientia
Visit the Call For Proposals page for more information